Home>Topics>Companies>IMS Health

IMS Health RX

  1. All
  2. Commentary
  3. Headlines
    1. BRIEF-Cegedim says definitive deal executed for its CRM and strategic data division with IMS Health


      Mon, 20 Oct 2014

      * Says definitive deal has been executed for its CRM and strategic data division with IMS Health Inc. for cash price of 385 million euros

    2. Belviq Sales Dip: What To Watch For Ahead


      Fri, 17 Oct 2014

      seasonality with ups and downs as the Fall weeks progress. This week sales declined 1.8% according to industry tracker IMS Health . Sales for the week ending October 10th were just under 12,200, representing a slight dip from the previous week

    3. Is It Time To Consider OncoMed Pharmaceuticals Again?


      Tue, 14 Oct 2014

      to between 20 million and 26 million. A report from IMS Health shows that despite moderating in recent years, global spending on oncology drugs reached $91 billion in 2013. IMS Health further notes in its report that the share of targeted

    4. IMS to report on October 24


      Fri, 10 Oct 2014

      IMS Health Holdings ( IMS -0.1% ) will report Q3 results on October 24 before the open. The conference call will begin at 9:00 am ET. Consensus view is EPS of $0.34 on revenues of $668M. Post your comment!

    5. Belviq Sales Flat - Model Your Expectations


      Fri, 3 Oct 2014

      Pharmaceuticals' (NASDAQ: ARNA ) Belviq were essentially flat this week vs. last week, according to industry tracker IMS Health (NYSE: IMS ). Script sales came in at about 11,800, and were down 0.5%. The numbers reported were as of September

    6. Akorn buys rights to bronchodilator


      Wed, 1 Oct 2014

      Akorn's top line and $0.07 - 0.08 to EPS in 2015 excluding the impact of acquisition-related amortization. Per IMS Health , the U.S. market for the branded and generic versions of Xopenex is ~$280M. Post your comment!

    7. IG Labs acquires products from Valeant


      Wed, 1 Oct 2014

      products from affiliates of Valeant Pharmaceuticals ( VRX -1.4% ). All have been approved via ANDAs or NDAs. Per IMS Health , the U.S. market for the drugs is ~$38M. Specific financial terms of the transaction are undisclosed. Post your

    8. Belviq Sales Benefit From Advertising - Up 2.8%


      Fri, 26 Sep 2014

      Pharmaceuticals (NASDAQ: ARNA ) saw a nice week over week gain on the heels of a more robust advertising campaign. According to IMS Health , script sales this week were about 11,900 which represents a gain of 2.8% over last weeks numbers. While a 2

    9. IG Labs acquires drug portfolio from AstraZeneca


      Thu, 25 Sep 2014

      been cleared by the FDA via ANDAs or NDAs prior to their discontinuation or withdrawal from the market. According to IMS Health , the U.S. addressable market for the products is ~$200M. Almost half of the 18 drugs are on the FDA shortage list

    10. Dr. Reddy's launches generic Xopenex in U.S.


      Wed, 24 Sep 2014

      generic version of Sunovion Pharmaceuticals' Xopenex (levalbuterol hydrochloride) inhalation solution. According to IMS Health , the U.S. market is ~$270M. Post your comment!

    « Prev12345Next »
    Content Partners